Last reviewed · How we verify

SGLT2 inhibitor, GLP-1 RA

Brigham and Women's Hospital · FDA-approved active Small molecule

SGLT2 inhibitor, GLP-1 RA is a SGLT2 inhibitor / GLP-1 receptor agonist combination Small molecule drug developed by Brigham and Women's Hospital. It is currently FDA-approved for Type 2 diabetes mellitus, Cardiovascular risk reduction in type 2 diabetes.

This dual-action drug combines SGLT2 inhibition (reducing glucose reabsorption in the kidney) with GLP-1 receptor agonism (enhancing insulin secretion and satiety) to lower blood glucose and body weight.

This dual-action drug combines SGLT2 inhibition (reducing glucose reabsorption in the kidney) with GLP-1 receptor agonism (enhancing insulin secretion and satiety) to lower blood glucose and body weight. Used for Type 2 diabetes mellitus, Cardiovascular risk reduction in type 2 diabetes.

At a glance

Generic nameSGLT2 inhibitor, GLP-1 RA
SponsorBrigham and Women's Hospital
Drug classSGLT2 inhibitor / GLP-1 receptor agonist combination
TargetSGLT2 and GLP-1R
ModalitySmall molecule
Therapeutic areaDiabetes, Cardiovascular
PhaseFDA-approved

Mechanism of action

SGLT2 inhibitors block sodium-glucose cotransporter 2 in the proximal tubule, promoting urinary glucose excretion independent of insulin. GLP-1 receptor agonists activate GLP-1 receptors on pancreatic beta cells and in the brain, stimulating glucose-dependent insulin secretion and reducing appetite. The combination provides complementary glucose-lowering and weight-loss effects with potential cardiovascular and renal benefits.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about SGLT2 inhibitor, GLP-1 RA

What is SGLT2 inhibitor, GLP-1 RA?

SGLT2 inhibitor, GLP-1 RA is a SGLT2 inhibitor / GLP-1 receptor agonist combination drug developed by Brigham and Women's Hospital, indicated for Type 2 diabetes mellitus, Cardiovascular risk reduction in type 2 diabetes.

How does SGLT2 inhibitor, GLP-1 RA work?

This dual-action drug combines SGLT2 inhibition (reducing glucose reabsorption in the kidney) with GLP-1 receptor agonism (enhancing insulin secretion and satiety) to lower blood glucose and body weight.

What is SGLT2 inhibitor, GLP-1 RA used for?

SGLT2 inhibitor, GLP-1 RA is indicated for Type 2 diabetes mellitus, Cardiovascular risk reduction in type 2 diabetes.

Who makes SGLT2 inhibitor, GLP-1 RA?

SGLT2 inhibitor, GLP-1 RA is developed and marketed by Brigham and Women's Hospital (see full Brigham and Women's Hospital pipeline at /company/brigham-and-women-s-hospital).

What drug class is SGLT2 inhibitor, GLP-1 RA in?

SGLT2 inhibitor, GLP-1 RA belongs to the SGLT2 inhibitor / GLP-1 receptor agonist combination class. See all SGLT2 inhibitor / GLP-1 receptor agonist combination drugs at /class/sglt2-inhibitor-glp-1-receptor-agonist-combination.

What development phase is SGLT2 inhibitor, GLP-1 RA in?

SGLT2 inhibitor, GLP-1 RA is FDA-approved (marketed).

What are the side effects of SGLT2 inhibitor, GLP-1 RA?

Common side effects of SGLT2 inhibitor, GLP-1 RA include Nausea, Genital mycotic infections, Polyuria, Gastrointestinal disturbance.

What does SGLT2 inhibitor, GLP-1 RA target?

SGLT2 inhibitor, GLP-1 RA targets SGLT2 and GLP-1R and is a SGLT2 inhibitor / GLP-1 receptor agonist combination.

Related